Our Primary Areas of Interest
The rapidly expanding repertoire of cancer therapies has provided an unprecedented improvement in cancer survival. Unfortunately, the advancement in cancer treatments lead to cardiac dysfunction and currently, cardiac toxicity related to cancer therapy is a main cause of death in cancer survivors.
We aim at providing new insights into the genetic, cellular, molecular, and functional mechanisms associated with cancer therapy related cardiac dysfunction at the individual level and at identifying novel cardio-protective strategies.
Modeling Heart Failure with Preserved Ejection Fraction (HFpEF)
Heart failure (HF) is a pandemic affecting more than 2% of the general population worldwide. Heart failure with preserved ejection fraction (HFpEF), has currently no effective medical therapy. A key reason for the failure to identify effective therapies is the lack of a suitable disease model for HFpEF. We aim at applying Cardiovascular technology to develop a novel in-vitro model for HFpEF.
Cardiovascular Organoid Maturation
We aim to develop and engineer multicellular cardiovascular organoids that will better mimic the adult human myocardium than currently available conventional technologies.
The platform generated may be implicated in disease modeling, drug discovery, toxicity screening, and myocardial regeneration.
Our aim is to further develop technologies for facilitating cardiovascular maturation.